Sign up to save your podcasts
Or
Share RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD
He describes where he sees AXPAXLI fitting into the treatment paradigm, and shares an update on the SOL-1 and SOL-R studies - including the rationale for recent changes to them. Plus an update on the NPDR indication.
View all episodes
By BiotechTV
4.3
66 ratings
He describes where he sees AXPAXLI fitting into the treatment paradigm, and shares an update on the SOL-1 and SOL-R studies - including the rationale for recent changes to them. Plus an update on the NPDR indication.
More shows like BiotechTV - News
View all
Motley Fool Money
3,222 Listeners
Odd Lots
1,910 Listeners
The Long Run with Luke Timmerman
124 Listeners
The Readout Loud
324 Listeners
Biotech 2050 Podcast
61 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,957 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Business Breakdowns
353 Listeners
Biotech Hangout
19 Listeners
Bloomberg Tech
60 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
512 Listeners
Uncapped with Jack Altman
41 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
2 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners
Cheeky Pint
48 Listeners